VHL loss of function and its impact on oncogenic signaling networks in clear cell renal cell carcinoma.

[1]  Héctor Guillén-Ahlers.  Wnt signaling in renal cancer. , 2008, Current drug targets.

[2]  E. Dahl,et al.  Frequent loss of SFRP1 expression in multiple human solid tumours: association with aberrant promoter methylation in renal cell carcinoma , 2007, Oncogene.

[3]  Mala Sinha,et al.  Secreted Frizzled-Related Protein 1 Loss Contributes to Tumor Phenotype of Clear Cell Renal Cell Carcinoma , 2007, Clinical Cancer Research.

[4]  P. Choyke,et al.  Identification of the Genes for Kidney Cancer: Opportunity for Disease-Specific Targeted Therapeutics , 2007, Clinical Cancer Research.

[5]  A. C. Williams,et al.  Interaction between β-catenin and HIF-1 promotes cellular adaptation to hypoxia , 2007, Nature Cell Biology.

[6]  M. Ohh,et al.  The Role of VHL in the Regulation of E-Cadherin: A New Connection in an Old Pathway , 2007, Cell cycle.

[7]  R. Dahiya,et al.  Wnt Antagonist Family Genes as Biomarkers for Diagnosis, Staging, and Prognosis of Renal Cell Carcinoma Using Tumor and Serum DNA , 2006, Clinical Cancer Research.

[8]  Hans Clevers,et al.  Wnt/β-Catenin Signaling in Development and Disease , 2006, Cell.

[9]  G. Dressler.  The cellular basis of kidney development. , 2006, Annual review of cell and developmental biology.

[10]  D. Bottaro,et al.  The von Hippel–Lindau tumor suppressor gene product represses oncogenic β-catenin signaling in renal carcinoma cells , 2006, Proceedings of the National Academy of Sciences.

[11]  J. Rubin,et al.  Secreted WNT antagonists as tumor suppressors: pro and con. , 2006, Frontiers in bioscience : a journal and virtual library.

[12]  Youhua Liu,et al.  Renal fibrosis: new insights into the pathogenesis and therapeutics. , 2006, Kidney international.

[13]  F. Brembeck,et al.  Essential role of BCL9-2 in the switch between beta-catenin's adhesive and transcriptional functions. , 2004, Genes & development.

[14]  M. Sakaguchi,et al.  Decreased expression of REIC/Dkk-3 in human renal clear cell carcinoma. , 2004, The Journal of urology.

[15]  W. Birchmeier,et al.  Met, metastasis, motility and more , 2003, Nature Reviews Molecular Cell Biology.

[16]  A. Perantoni.  Renal development: perspectives on a Wnt-dependent process. , 2003, Seminars in cell & developmental biology.

[17]  W. Kaelin,et al.  Molecular basis of the VHL hereditary cancer syndrome , 2002, Nature Reviews Cancer.

[18]  K. Matsumoto,et al.  Hepatocyte growth factor: renotropic role and potential therapeutics for renal diseases. , 2001, Kidney international.

[19]  J. Barasch,et al.  Activation of Hepatocyte Growth Factor (HGF) by Endogenous HGF Activator Is Required for Metanephric Kidney Morphogenesis in Vitro * , 2001, The Journal of Biological Chemistry.

[20]  S. Segerer,et al.  Metanephrogenic mesenchyme-to-epithelium transition induces profound expression changes of ion channels. , 2000, American journal of physiology. Renal physiology.

[21]  P. Schofield,et al.  Expression of the von Hippel-Lindau disease tumour suppressor gene during human embryogenesis. , 1996, Human molecular genetics.

[22]  A. C. Williams,et al.  Interaction between beta-catenin and HIF-1 promotes cellular adaptation to hypoxia. , 2007, Nature cell biology.

[23]  K. Eckardt,et al.  Expression of hypoxia-inducible transcription factors in developing human and rat kidneys. , 2006, Kidney international.

[24]  H. Clevers.  Wnt/beta-catenin signaling in development and disease. , 2006, Cell.